These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: ARK5 promotes glioma cell invasion, and its elevated expression is correlated with poor clinical outcome.
    Author: Lu S, Niu N, Guo H, Tang J, Guo W, Liu Z, Shi L, Sun T, Zhou F, Li H, Zhang J, Zhang B.
    Journal: Eur J Cancer; 2013 Feb; 49(3):752-63. PubMed ID: 23063350.
    Abstract:
    Poor prognosis of malignant gliomas is primarily attributed to their highly invasive nature. Despite the identification of new biomarkers and molecular targets for the improvement of the diagnosis, prognosis and treatment of glioma, the overall prognosis of the disease remains poor. This study is the first to show the significant upregulation of ARK5 paraffin-embedded archival glioma biopsies compared with those in adjacent non-cancerous brain tissues. Statistical analysis suggests that the upregulation of ARK5 correlates with the World Health Organization grade of glioma (P<0.001) and that patients with a high ARK5 level exhibit shorter survival time (P<0.01). In addition, ARK5 can promote glioma cell invasion by regulating cytoskeleton rearrangement and matrix metalloproteinase activation. ARK5 knockdown was found to reduce brain invasion in a glioma xenograft mouse model. Our results strongly suggest that ARK5 represents a novel and valuable biomarker to aid in the prediction of patient prognosis and is a potential therapeutic target against glioma.
    [Abstract] [Full Text] [Related] [New Search]